Recruiting NCT07226726

Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

Phase I Interventional Congenital Myasthenic Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: AlloEx exosomes.
Who it may be relevant to: Registry conditions: Congenital Myasthenic Syndrome. Basic parameters: from 18 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: United States, Antigua and Barbuda
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Official title

Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Detailed description

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

Biological AlloEx exosomes
This is an intranasal treatment of exosomes derived from mesenchymal stem cells.

Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
Patients must be able to provide informed consent, or have a guardian who does.
Patient must be able to travel to the site of treatment.

Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

United States · 2 centers

Antigua and Barbuda · 1 center

NCT: NCT07226726 · FOREM2025-CMS1